Ischemia Reperfusion Injury Market

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Ischemia Reperfusion Injury Market contains market size and forecasts of Ischemia Reperfusion Injury in Global, including the following market information:

• Global Ischemia Reperfusion Injury Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Ischemia Reperfusion Injury market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Phase 1 Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ischemia Reperfusion Injury include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, Opsona Therapeutics, Pharming, TheraSource, Bolder Biotechnology, Corline Biomedical and Mifcortx, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ischemia Reperfusion Injury companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ischemia Reperfusion Injury Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Ischemia Reperfusion Injury Market Segment Percentages, by Type, 2021 (%)

• Phase 1
• Phase 2
• Preclinical

Global Ischemia Reperfusion Injury Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Ischemia Reperfusion Injury Market Segment Percentages, by Application, 2021 (%)

• Heart Injury
• Kidney Injury
• Intestine Injury
• Other Injury

Global Ischemia Reperfusion Injury Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Ischemia Reperfusion Injury Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Ischemia Reperfusion Injury revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Ischemia Reperfusion Injury revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Angion Biomedica
• Catalyst Biosciences
• Ischemix Inc
• Opsona Therapeutics
• Pharming
• TheraSource
• Bolder Biotechnology
• Corline Biomedical
• Mifcortx
• Balmes Transplantation
• NovelMed Therapeutics
• Hope Pharmaceuticals
• Omeros Corp
• Prothix
• SBI Pharmaceuticals